BioSpace News Archive

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the publication in The Journal of Infectious Diseases of the Phase 1 results of HOOKIPA’s VaxWave ® -based prophylactic Cytomegalovirus (CMV) vaccine candidate HB-101, which is currently in a Phase 2 clinical trial. The pap

A consortium of leading healthcare companies today announced the launch of the COVID-19 Research Database , a secure repository of HIPAA-compliant, de-identified and limited patient-level data sets made available to public health and policy researchers to extract insights to help combat the COVID-19 pandemic. The database is a

Forma Therapeutics, Inc. (“Forma”), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will be presenting an electronic poster at the American Association for Cancer Research (AACR) taking place virtually June 22-24, 2020

Management to host webcast and conference call to review data and program strategy at 8:30 a.m. ET on April 28, 2020

Mogrify Ltd and Sangamo Therapeutics announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells and embryonic stem cells and Sangamo’s zinc finger protein gene-engineered chimeric antigen receptor regulatory T cell technology.

Dr. Golan, an infectious disease thought leader at Tufts Medical Center, fills key clinical position to help advance Appili’s infectious disease portfolio

– Overall response rate of 22% – – Disease control rate of 71% – – Median overall survival of 21 months – – Key topline data from ILLUMINATE-301 expected in Q1 2021 –

Acerus Announces Publication of Results for NATESTO ® Spermatogenesis Study in Journal of Urology

Simplify Medical Pty Ltd., maker of the Simplify® cervical artificial disc, announced the completion of the Pre-Market Approval submission for the 1-level Simplify Disc IDE Study to the U.S. Food and Drug Administration.

AzurRx BioPharma, Inc. issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer.